Weight Loss$100–$155

Cagrilintide: Dosage, Benefits & Side Effects

By Peptide Assistant Editorial Team · · · 12 sources cited

Overview

Cagrilintide is a long-acting acylated amylin analog developed by Novo Nordisk that reduces appetite and food intake by activating amylin receptors in the brainstem — a satiety pathway distinct from and complementary to GLP-1 signaling. When combined with semaglutide in the CagriSema formulation, it produced a mean 20.4% body weight reduction at 68 weeks in the Phase III REDEFINE 1 trial. As a standalone agent, cagrilintide produces meaningful weight loss that validates amylin as a major therapeutic target in obesity.

Mechanism of Action

Cagrilintide is a synthetic analog of amylin, a 37-amino-acid hormone co-secreted with insulin from pancreatic β-cells in response to meals. It activates amylin receptors (AMY1 and AMY3) — heterodimeric complexes of the calcitonin receptor (CTR) with receptor activity-modifying proteins (RAMP1 and RAMP3, respectively). These receptors are concentrated in the area postrema and nucleus tractus solitarius of the brainstem. Activation of brainstem amylin receptors produces three primary effects: (1) slowing of gastric emptying, extending the physical sensation of fullness after meals; (2) suppression of postprandial glucagon secretion from pancreatic α-cells, improving glucose homeostasis; (3) direct satiety signaling to higher brain centers, reducing meal size and food-seeking behavior. The acylation modification (attachment of a fatty acid chain) allows cagrilintide to bind to serum albumin, dramatically extending its half-life and enabling once-weekly dosing. This pharmacokinetic optimization is the same strategy used in semaglutide and liraglutide. Critically, amylin and GLP-1 signal through anatomically and mechanistically distinct satiety pathways — amylin acts mainly through the brainstem area postrema, while GLP-1 agonists act on both brainstem and hypothalamic sites (shown for semaglutide in rodents). Combining cagrilintide with a GLP-1 agonist engages two receptor systems at once, and in trials the combination produced more weight loss than either drug alone.

Cagrilintide Benefits: What the Research Shows

  • The REDEFINE 1 Phase III trial (2025, NEJM, n=3,417) found CagriSema achieved 20.4% mean body weight reduction at 68 weeks, compared to 3.0% with placebo; the trial also included semaglutide-alone and cagrilintide-alone arms.
  • Across randomized trials, CagriSema participants were about twice as likely as those on semaglutide 2.4 mg alone to lose ≥20% of body weight (pooled risk ratio 2.10).
  • Phase II monotherapy data showed cagrilintide produced up to 10.8% body weight reduction at the 4.5 mg dose over 26 weeks — clinically meaningful as a standalone agent.
  • Glycemic control: in a 32-week Phase II trial in type 2 diabetes, CagriSema reduced HbA1c by 2.2 percentage points, versus 1.8 with semaglutide (difference not significant) and 0.9 with cagrilintide; the Phase III REIMAGINE 2 trial later found a small but significant advantage over semaglutide 2.4 mg (1.91 vs. 1.75).
  • The amylin receptor pathway validated as a complementary target to GLP-1, establishing the scientific basis for dual-mechanism appetite suppression.
  • Dose-dependent weight loss with an acceptable GI tolerability profile similar to semaglutide when dose-escalated appropriately.

Cagrilintide Dosage

  • Clinical trial doses: 1.2 mg, 2.4 mg, or 4.5 mg subcutaneous injection once weekly. The 2.4 mg dose was used in the pivotal CagriSema Phase III combination trial.
  • Dose escalation: Start at the lowest dose (0.25–0.5 mg weekly) and escalate over 8–16 weeks to the target dose. Gradual escalation is critical for minimizing nausea and GI side effects.
  • CagriSema combination protocol: 2.4 mg cagrilintide + 2.4 mg semaglutide, co-injected once weekly. Dose escalation applies to both components.
  • Research vials (5–10 mg): Reconstitute with bacteriostatic water. Calculate weekly dose based on concentration and desired mg amount.
  • Inject subcutaneously in the abdomen, thigh, or upper arm. Rotate injection sites weekly.
  • Nausea management during escalation: slow the escalation schedule if nausea is severe. Ginger supplements, small frequent meals, and ondansetron can help.
  • No specific food timing requirements, though some users prefer injecting in the evening to sleep through the initial nausea.
Cagrilintide dosage calculator: get your dose in syringe units →

Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.

Cagrilintide Side Effects & Safety

Known Side Effects

  • Nausea — the most common side effect, affecting 20–47% of patients depending on dose in the Phase II trial (18% on placebo). Most prevalent during the first 4–8 weeks and improving with continued use.
  • Vomiting — reported in 10–15% of patients, primarily during dose escalation. Usually resolves with slower titration.
  • Diarrhea — affects approximately 10–20% of users, more common at higher doses.
  • Constipation — paradoxically reported alongside diarrhea in some patients, reflecting slowed gastric motility.
  • Injection site reactions — mild pain, redness, or swelling at the injection site.
  • Decreased appetite — technically the desired effect, but in some patients the appetite suppression can be excessive, requiring dose adjustment.
  • Potential for pancreatitis — reported after marketing with the amylin analog pramlintide, though a causal link has not been established.

Safety Profile

Cagrilintide's safety has been studied in Phase II and Phase III clinical trials involving thousands of patients, mostly in combination with semaglutide and for up to 68 weeks; it is not FDA-approved. The GI side effect profile (nausea, vomiting, diarrhea) is consistent with the amylin agonist mechanism and is generally manageable with appropriate dose escalation. Serious adverse events were uncommon in clinical trials, though one meta-analysis found them more frequent with cagrilintide alone than with semaglutide. Cagrilintide has no approved label, so it has no formal contraindications. The medullary thyroid carcinoma and MEN2 contraindication belongs to GLP-1 agonists such as semaglutide, so it is relevant to the CagriSema combination; the label of the approved amylin analog pramlintide carries no thyroid warning. History of pancreatitis warrants caution. Not recommended in pregnancy or breastfeeding. Concurrent use with other amylin analogs (pramlintide) or insulin should be carefully managed due to additive hypoglycemic risk. As of an FDA statement current in October 2026, cagrilintide was not a component of any FDA-approved drug.

What to Expect

Weeks 1–4 (escalation phase): GI side effects are most prominent during this period. Appetite reduction begins even at lower doses. Most users notice reduced interest in food, smaller portion sizes, and less snacking. Weight loss of 2–4 lbs is common even during escalation. Weeks 5–12: As the target dose is reached, appetite suppression strengthens. Weight loss accelerates. Nausea diminishes for most users. Typical weight loss is 1–2 lbs per week at this stage. Weeks 13–26: Steady-state weight loss. The rate may slow from the initial pace but remains clinically significant. Metabolic improvements (fasting glucose, HbA1c, lipids) become apparent on blood work. Cagrilintide monotherapy typically produces 8–11% total body weight loss by this point. Weeks 27–68+: Continued gradual weight loss with eventual plateau at a new lower set point. The CagriSema combination data showed 20.4% mean loss at 68 weeks, with some patients achieving >30%. Maintenance dosing is likely required long-term.

Common Stacks

Storage & Handling

Research vials: store lyophilized powder refrigerated at 36–46°F (2–8°C). After reconstitution with bacteriostatic water, refrigerate and use within 4 weeks. Do not freeze reconstituted solution. Pharmaceutical pre-filled pens (when available): follow manufacturer storage instructions, typically refrigerated with room-temperature allowances for daily use.

Pricing & Available Variants

$100 – $155price range
5mg10mg

Prices sourced from peptides.gg marketplace. Prices may vary.

References

  1. Lau DCW, Erichsen L, Francisco AM, et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet. 2021.
  2. Garvey WT, Blüher M, Osorto Contreras CK, et al. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2025.
  3. Frias JP, Deenadayalan S, Erichsen L, et al. Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet. 2023.
  4. Buse JB, Bajaj HS, Dalskov SM, et al. Cagrilintide-semaglutide (CagriSema) versus semaglutide or cagrilintide in people with type 2 diabetes (REIMAGINE 2): a double-blind, randomised, controlled, phase 3 study. Lancet Diabetes Endocrinol. 2026.
  5. Rasool ZK, Shah R, Batool AEZ, et al. CagriSema versus Semaglutide 2.4 mg monotherapy for weight management in adults with overweight or obesity, with or without type 2 diabetes: a systematic review, meta-analysis, and trial sequential analysis. Front Endocrinol (Lausanne). 2026.
  6. Enebo LB, Berthelsen KK, Kankam M, et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of concomitant administration of multiple doses of cagrilintide with semaglutide 2·4 mg for weight management: a randomised, controlled, phase 1b trial. Lancet. 2021.
  7. Kruse T, Hansen JL, Dahl K, et al. Development of Cagrilintide, a Long-Acting Amylin Analogue. J Med Chem. 2021.
  8. Le Foll C, Lutz TA. Amylin: A Multi-Functional Pancreatic Hormone-A Review. Diabetes Obes Metab. 2026.
  9. Ahmed M, Hassan M, Tahir M, et al. Efficacy and Safety of Cagrilintide and Cagrisema Versus Semaglutide as Anti-Obesity Medications: A Systematic Review, Meta-Analysis and Meta-Regression. Diabetes Obes Metab. 2026.
  10. Gabery S, Salinas CG, Paulsen SJ, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020.
  11. SymlinPen (pramlintide acetate) injection: prescribing information. AstraZeneca, via DailyMed. 2024.
  12. FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss. U.S. Food and Drug Administration. 2026.

Related Peptides

Track Cagrilintide in Your Protocol

Log your Cagrilintide doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.

Start Tracking Free